i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135, Porto, Portugal; IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, 4200-135, Porto, Portugal.
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135, Porto, Portugal; IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, 4200-135, Porto, Portugal; ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, 4050-313, Porto, Portugal; FMUP - Faculty of Medicine, University of Porto, 4200-319, Porto, Portugal.
Trends Cancer. 2022 Jun;8(6):448-455. doi: 10.1016/j.trecan.2022.02.003. Epub 2022 Mar 6.
Although the ErbB receptors remain incontrovertible drivers of human neoplastic transformation, the clinical performance of ErbB-directed therapeutics is significantly undermined by the emergence of molecular resistance. The ErbB extracellular region undergoes extensive post-translational glycosylation, which crucially impacts receptor structure, functionality, and therapeutic response, thereby hindering efforts towards the successful translation of such molecular insights into the clinical setting. The unraveling of the ErbB site-specific glycome will allow for the design of more efficient ErbB-directed therapeutic strategies capable of circumventing molecular resistance, the establishment of novel prognostic and predictive clinical biomarkers supporting improved patient stratification, and the rational guidance of therapeutic decisions.
虽然 ErbB 受体仍然是人类肿瘤转化不可争议的驱动因素，但 ErbB 靶向治疗的临床效果因分子耐药性的出现而显著降低。ErbB 细胞外区域经历广泛的翻译后糖基化，这对受体结构、功能和治疗反应至关重要，从而阻碍了将这些分子见解成功转化为临床环境的努力。阐明 ErbB 位点特异性聚糖组将能够设计更有效的能够规避分子耐药性的 ErbB 靶向治疗策略，建立支持改善患者分层的新的预后和预测性临床生物标志物，并合理指导治疗决策。
